Redeye provides its first take on Camurus’ Q2 report 2025, published this morning. Sales of Buvidal and Brixadi were below our forecast, but this was largely due to negative currency effects, without which they were essentially in line with our forecast. Total revenues handsomely exceeded our forecast, thanks to the upfront payment of USD12m from Eli Lilly. Operating costs were also lower than we had projected.
LÄS MER
